Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07054346 · ClinicalTrials.gov registry record · Phase 1

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

A Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma, sponsored by Thomas Hope.

Recruiting
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT07054346 is a Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 45 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07054346, a Phase 1 study of Prostate Cancer and Localized Prostate Carcinoma, is actively recruiting participants, sponsored by Thomas Hope.

RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.

Conditions Studied

Prostate Cancer Localized Prostate Carcinoma Prostate Cancer (Diagnosis) High-risk Prostate Cancer Very High Risk Prostate Carcinoma

Interventions

  • DRUG 177 Lutetium Prostate-Specific Membrane Antigen 617
  • DRUG Actinium-225 Prostate-Specific Membrane Antigen 617
  • PROCEDURE Non-investigational, Prostatectomy
  • PROCEDURE Prostate Tissue Collection
  • PROCEDURE Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2025-07-08
Est. Completion 2028-04-30
Phase Phase 1

Sponsor

Thomas Hope

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07054346

The ClinicalTrials.gov registry entry for NCT07054346 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which 177 Lutetium Prostate-Specific Membrane Antigen 617 is the first listed.

NCT07054346 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07054346 about?

NCT07054346 is a clinical study titled "Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617". There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of act...

What is the current status of trial NCT07054346?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-07-08. Estimated completion is 2028-04-30.

What conditions does trial NCT07054346 study?

This clinical trial studies the following conditions: Prostate Cancer, Localized Prostate Carcinoma, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Very High Risk Prostate Carcinoma.

What interventions are being tested in trial NCT07054346?

The interventions under investigation include: 177 Lutetium Prostate-Specific Membrane Antigen 617 (DRUG), Actinium-225 Prostate-Specific Membrane Antigen 617 (DRUG), Non-investigational, Prostatectomy (PROCEDURE), Prostate Tissue Collection (PROCEDURE), Single-photon emission computed tomography (SPECT)/Computerized tomography (CT) (PROCEDURE).

Who is sponsoring clinical trial NCT07054346?

This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07054346 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Localized Prostate Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.